Physician profile
Robert Alan Schuster
NPI 1871525931
$12,383.72
in general payments reported to CMS, 2019-2025
35 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $1,173 · 2021: $1,682 · 2022: $1,765 · 2023: $1,986 · 2024: $2,211 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,801 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,800.67 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,534.13 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $1,465.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Alkermes, INC. | $1,393.14 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,092.36 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,023.97 | 2020-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,003.76 | 2021-2025 | Vraylar, Qulipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $850.88 | 2020-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $793.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $476.92 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $474.30 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $433.02 | 2020-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Allergan, INC. | $390.89 | 2019-2021 | |
| Amgen INC. | $181.86 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $173.72 | 2021-2024 | Trintellix |
| Novo Nordisk INC | $131.35 | 2020-2025 | Ozempic |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.22 | 2019-2024 | |
| Lundbeck LLC | $111.54 | 2021-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $89.81 | 2022 | |
| Axsome Therapeutics, INC. | $82.40 | 2023-2024 | Auvelity |
| Astellas Pharma US INC | $79.99 | 2024 | |
| Indivior INC. | $78.20 | 2019-2022 | |
| Mylan Specialty L.P. | $52.26 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.43 | 2020-2022 | |
| Ardelyx, INC. | $42.53 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $37.47 | 2022 | |
| Lilly USA, LLC | $34.08 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $30.35 | 2021 | |
| Philips North America LLC | $26.15 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| Shire North American Group INC | $22.97 | 2019 | |
| Inspire Medical Systems, INC. | $22.40 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $22.15 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.36 | 2025 | Cobenfy |
| Xeris Pharmaceuticals, INC. | $18.17 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $17.01 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.